InSitu Biologics operates as a developing biotechnology firm that focuses on advancing a multi-phase extended release medication delivery system for localized treatment of pain, cancer, and infection. The company utilizes innovative technology to tackle the unmet demands in the pain management and medication distribution sectors. InSitu Biologics is presently in the investigational preclinical phase and its products are not yet available for purchase in any region.